Press Release Archive: 2010 | 2009 | 2008 | 2007 | 2005 | View All
Press Releases |
ENB-0040, A Bone Targeted Enzyme Replacement Therapy, Shows Promise in Children with HypophosphatasiaJune 21, 2010Enobia Presents Results from Hypophosphatasia Impact Patient SurveyMarch 29, 2010Enobia Expands Clinical Program for ENB-0040, a Bone-targeted Enzyme Replacement Therapy for HypophosphatasiaNovember 02, 2009Enobia Announces Positive Clinical Results with ENB-0040, a Bone Targeted Enzyme Replacement Therapy for HypophosphatasiaSeptember 14, 2009Enobia Raises US$50M from Current Investors in Series C FinancingAugust 10, 2009Enobia Announces Positive Interim Clinical Results with ENB-0040June 11, 2009Enobia Pharma's ENB-0040 receives FDA fast track designationMay 19, 2009Enobia completes target enrollment in clinical trial for infantile HypophosphatasiaMarch 03, 2009Enobia initiates infantile enzyme replacement trial for rare bone diseaseDecember 01, 2008Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management TeamSeptember 22, 2008